NASDAQ:RNXT RenovoRx (RNXT) Stock Price, News & Analysis $0.99 +0.03 (+3.14%) Closing price 04:00 PM EasternExtended Trading$0.98 -0.01 (-0.72%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About RenovoRx Stock (NASDAQ:RNXT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get RenovoRx alerts:Sign Up Key Stats Today's Range$0.97▼$1.0150-Day Range$0.77▼$1.0752-Week Range$0.75▼$1.69Volume112,646 shsAverage Volume75,691 shsMarket Capitalization$36.19 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company OverviewRenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.Read More… RenovoRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreRNXT MarketRank™: RenovoRx scored higher than 43% of companies evaluated by MarketBeat, and ranked 489th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingRenovoRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRenovoRx has only been the subject of 2 research reports in the past 90 days.Read more about RenovoRx's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for RenovoRx are expected to decrease in the coming year, from ($0.40) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RenovoRx is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RenovoRx is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about RenovoRx's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.84% of the float of RenovoRx has been sold short.Short Interest Ratio / Days to CoverRenovoRx has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RenovoRx has recently increased by 12.12%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRenovoRx does not currently pay a dividend.Dividend GrowthRenovoRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.84% of the float of RenovoRx has been sold short.Short Interest Ratio / Days to CoverRenovoRx has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RenovoRx has recently increased by 12.12%, indicating that investor sentiment is decreasing significantly. News and Social Media2.3 / 5News Sentiment0.22 News SentimentRenovoRx has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for RenovoRx this week, compared to 1 article on an average week.Search Interest2 people have searched for RNXT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, RenovoRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $90,218.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.10% of the stock of RenovoRx is held by insiders.Percentage Held by InstitutionsOnly 3.10% of the stock of RenovoRx is held by institutions.Read more about RenovoRx's insider trading history. Receive RNXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RenovoRx and its competitors with MarketBeat's FREE daily newsletter. Email Address RNXT Stock News HeadlinesRamtin Agah Purchases 15,000 Shares of RenovoRx, Inc. (NASDAQ:RNXT) StockApril 18, 2025 | insidertrades.comRenovoRx, Inc. (NASDAQ:RNXT) Insider Acquires $16,000.00 in StockApril 15, 2025 | insidertrades.comMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millions of years. And both grizzled oilmen and clean energy supporters love it: Energy Secretary Chris Wright called it "an awesome resource," while Warren Buffett, Jeff Bezos, Mark Zuckerberg, and Bill Gates are all directly invested.May 1, 2025 | Stansberry Research (Ad)RenovoRx, Inc. (NASDAQ:RNXT) Director Laurence Marton Purchases 12,050 SharesApril 11, 2025 | insidertrades.comRenovoRx, Inc. (NASDAQ:RNXT) Insider Buys $21,840.00 in StockApril 10, 2025 | insidertrades.comRenovoRx (NASDAQ:RNXT) Given New $11.00 Price Target at Ascendiant Capital MarketsApril 30 at 2:01 AM | americanbankingnews.comJohns Hopkins rejoint l’essai TIGeR-PaC de RenovoRx sur le cancer du pancréasApril 29 at 10:28 AM | fr.investing.comJohns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical TrialApril 29 at 10:28 AM | finance.yahoo.comSee More Headlines RNXT Stock Analysis - Frequently Asked Questions How have RNXT shares performed this year? RenovoRx's stock was trading at $1.29 on January 1st, 2025. Since then, RNXT shares have decreased by 23.2% and is now trading at $0.9901. View the best growth stocks for 2025 here. How were RenovoRx's earnings last quarter? RenovoRx, Inc. (NASDAQ:RNXT) posted its earnings results on Monday, March, 31st. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.01. The firm earned $0.04 million during the quarter, compared to the consensus estimate of $0.17 million. When did RenovoRx IPO? RenovoRx (RNXT) raised $18 million in an IPO on Thursday, August 26th 2021. The company issued 1,800,000 shares at a price of $9.00-$11.00 per share. Roth Capital Partners and Maxim Group LLC served as the underwriters for the IPO. How do I buy shares of RenovoRx? Shares of RNXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of RenovoRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that RenovoRx investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), Bakkt (BKKT), NIO (NIO) and Phunware (PHUN). Company Calendar Last Earnings3/31/2025Today5/01/2025Next Earnings (Estimated)5/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RNXT CIK1574094 Webwww.renovorx.com Phone650-284-4433Fax650-397-4433Employees6Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$11.00 Low Stock Price Target$3.00 Potential Upside/Downside+607.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,230,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-205.96% Return on Assets-110.01% Debt Debt-to-Equity RatioN/A Current Ratio5.66 Quick Ratio5.66 Sales & Book Value Annual Sales$43,000.00 Price / Sales841.52 Cash FlowN/A Price / Cash FlowN/A Book Value($0.28) per share Price / Book-3.54Miscellaneous Outstanding Shares36,547,000Free Float22,297,000Market Cap$36.19 million OptionableNot Optionable Beta1.12 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:RNXT) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RenovoRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RenovoRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.